1207284-95-4

Upstream product

• 1207284-91-0 (4S,4aS,5aR,12aS)-13-(dimethylamino)-4a-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-8-(di-2-propen-1-ylamino)-10-fluoro-11a,12,12a,13-tetrahydro-5-hydroxy-3,7-bis(phenylmethoxy)-naphthaceno[2,3-d]isoxazole-4,6(4aH,11H)-dione 
• 1207284-92-1 (4S,4aS,5aR,12aS)-8-amino-13-(dimethylamino)-9-[ (dimethylamino)methyl]-4a-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-10-fluoro-11a,12,12a,13-tetrahydro-5-hydroxy-3,7-bis(phenylmethoxy)-naphthaceno[2,3-d]isoxazole-4,6(4aH,11H)-dione 
• 590-86-3 isovaleraldehyde 

Relevant academic research and scientific papers

Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy

Utilizing a fully synthetic route to tetracycline analogues, the C-9 side-chain of the fluorocyclines was optimized for both antibacterial activity and oral efficacy. Compounds were identified that overcome both efflux (tet(K), tet(A)) and ribosomal protection (tet(M)) tetracycline-resistance mechanisms and are active against Gram-positive and Gram-negative organisms. A murine systemic infection model was used as an oral efficacy screen to rapidly identify compounds with oral bioavailability. Two compounds were identified that exhibit both oral bioavailability in rat and clinically relevant bacterial susceptibility profiles against major respiratory pathogens. One compound demonstrated oral efficacy in rodent lung infection models that was comparable to marketed antibacterial agents.

C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS

The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.